Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.